Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: Results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study

Medical Journal of Australia

Volumn 189, Issue 2, 2008, Pages 105-109

  Nelson, Mark R ^a   Reid, Christopher M ^b   Ames, David A ^c   Beilin, Lawrence J ^d   Donnan, Geoffrey A ^c   Gibbs, Peter ^e   Johnston, Colin I ^f   Krum, Henry ^b   Storey, Elsdon ^g   Tonkin, Andrew ^b   Wolfe, Rory ^b   Woods, Robyn ^b   McNeil, John J ^b  

^a UNIVERSITY OF TASMANIA   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^f BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^g MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HEMOGLOBIN; PLACEBO;

AGED; ARTICLE; AUSTRALIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DOUBLE BLIND PROCEDURE; DRUG USE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GENERAL PRACTICE; GENERAL PRACTITIONER; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL;

EID: 49749120983     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2008.tb01932.x     Document Type: Article

References (26)

1. McNeil JJ, Nelson MR, Tonkin AM. Public funding of large-scale clinical trials in Australia. Med J Aust 2003; 179: 519-520.
2. Nelson MR, Reid CM, Beilin LJ, et al; ASPREE Study Group. Rationale for a primary prevention trial of low dose aspirin for major adverse cardiovascular events and vascular dementia in the elderly: ASPirin in Reducing Events in the Elderly (ASPREE). Drugs Aging 2003;20:897-903.
3. McNeil JJ, Woods R. ASPirin in Reducing Events in the Elderly. Protocol. http://www.med.monash.edu.au/epidemiology/downloads/ aspree-protocol-060308.pdf (accessed Jun 2008).
4. Reid C, Ryan P, Nelson M, et al. General practitioner participation in the Second Australian National Blood Pressure Study (ANBP2). Clin Exp Pharmacol Physiol 2001; 28: 663-667.
5. D'Elia LF, Satz P, Uchiyama CL, et al. Color Trails Test. Odessa, Fla: Psychology Assessment Resources, 1999.
6. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583-592.
7. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
8. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988; 296: 313-316.
9. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321: 129-135.
10. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
11. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998; 351: 233-241.
12. Hart RG, Halperin JL, McBride R, et al. Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. Arch Neurol 2000; 57: 326-332.
13. Collaborative Group of the Primary Prevention Project (PPP). Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001; 357: 89-95.
14. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease; a review of 17 epidemiologic studies. Neurology 1996; 47: 425-432.
15. Broe GA, Grayson DA, Creasey HM, et al. Anti-inflammatory drugs protect against Alzheimer disease at low doses. Arch Neurol 2000; 57: 1586-1591.
16. in 't Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimers disease. N Engl J Med 2001; 345: 1515-1521.
17. Nelson MR, Liew D, Bertram M, Vos T. Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged 70. BMJ 2005; 330: 1306-1308.
18. Nelson MR, Tonkin AM, Cicuttini FM, McNeil JJ. COX-2 inhibitors: exemplars of the drug-safety conundrum [editorial]. Med J Aust 2005; 182: 262-263.
19. Silagy CA, McNeil JJ, Donnan GA, et al. Adverse effects of low-dose aspirin in a healthy elderly population. Clin Pharmacol Ther 1993; 54: 84-89.
20. Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001; 37: 1775-1780.
21. Dedier J, Stampfer MJ, Hankinson SE, et al. Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension 2002; 40: 604-608.
22. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 136: 161-172.
23. Ridker PM, Cook NR, Lee I-M, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293-1304.
24. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373-2383.
25. Hennekens CH, Hollar D, Baigent C. Sex-related differences in response to aspirin in cardiovascular disease: an untested hypothesis. Nat Clin Pract Cardiovasc Med 2006; 3: 4-5.
26. United States of America Food and Drug Administration, Centre for Drug Evaluation and Research. Cardiovascular and Renal Drugs Advisory Committee meeting. 8 Dec 2003. http://www.fda.gov/ohrms/dockets/ac/03/ transcripts/4012T1.htm (accessed Jun 2008).